

Hyperoxaluria - Pipeline Insight, 2021

<https://marketpublishers.com/r/HAAE443D85AEN.html>

Date: March 2021

Pages: 120

Price: US\$ 1,500.00 (Single User License)

ID: HAAE443D85AEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Hyperoxaluria – Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Hyperoxaluria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

HYPEROXALURIA Understanding

HYPEROXALURIA: Overview

Hyperoxaluria is a condition that occurs when there is too much oxalate in the urine. Oxalate is a natural chemical in body and also contained in some foods, is normally eliminated from the body through the kidneys in the urine. Symptoms of hyperoxaluria can develop anytime from infancy to later adulthood (over 70 years of age). The most common initial symptom is usually kidney stones. Urine tests, Blood tests and scans may contribute to the diagnosis of Hyperoxaluria. The goal of treatment is to lower the level of oxalate in the body and prevent calcium oxalate crystals from forming in the kidneys and other body tissues.

'HYPEROXALURIA - Pipeline Insight, 2021' report by DelveInsight outlays

comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the HYPEROXALURIA pipeline landscape is provided which includes the disease overview and HYPEROXALURIA treatment guidelines. The assessment part of the report embraces, in depth HYPEROXALURIA commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HYPEROXALURIA collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence HYPEROXALURIA R&D. The therapies under development are focused on novel approaches to treat/improve HYPEROXALURIA.

HYPEROXALURIA Emerging Drugs Chapters

This segment of the HYPEROXALURIA report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

HYPEROXALURIA Emerging Drugs

Oxabact: OxaThera

Oxalobacter formigenes is an anaerobe, non-pathogenic bacterium which exclusively uses oxalate as the energy source. OxThera has taken this bacterial strain isolated from the human gut and developed a live biotherapeutic product candidate. Oxabact is being studied in phase III stage of development for the treatment of primary hyperoxaluria.

Reloxiliase: Allen Pharmaceuticals

Reloxaliase (formerly ALLN-177), is a first-in-class, non-absorbed, orally-administered enzyme for the treatment of hyperoxaluria. Reloxaliase, a crystalline formulation of the enzyme oxalate decarboxylase, has been designed to specifically degrade oxalate within the GI tract, thus limiting systemic absorption of oxalate into the bloodstream. Reloxiliase is being evaluated for the treatment of Hyperoxaluria in phase III stage of

development.

Stiripentol: Biocodex

Stiripentol is an orally active compound originated by Biocodex that inhibits several P450 cytochromes. Stiripentol developed by Biocodex is being studied in phase II stage of development for the treatment of primary Hyperoxaluria.

Further product details are provided in the report.....

HYPEROXALURIA: Therapeutic Assessment

This segment of the report provides insights about the different HYPEROXALURIA drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in HYPEROXALURIA

There are approx. 10+ key companies which are developing the therapies for HYPEROXALURIA. The companies which have their HYPEROXALURIA drug candidates in the most advanced stage, i.e. phase III include, OxaThera.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

HYPEROXALURIA pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Subcutaneous

Intravenous

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Bispecific Antibody

Peptides

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

HYPEROXALURIA: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses HYPEROXALURIA therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging HYPEROXALURIA drugs.

HYPEROXALURIA Report Insights

HYPEROXALURIA Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

HYPEROXALURIA Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing HYPEROXALURIA drugs?

How many Hyperoxaluria drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of HYPEROXALURIA?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the HYPEROXALURIA therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for HYPEROXALURIA and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

- Introduction
- Executive Summary
- HYPEROXALURIA: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- HYPEROXALURIA – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
 - HYPEROXALURIA companies’ collaborations, Licensing, Acquisition -Deal Value
- Trends
- HYPEROXALURIA Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- Oxabact: OxaThera
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Stiripentol: Biocodex
 - Product Description
 - Research and Development
 - Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis

SYNB8802: Synlogic

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical Stage Products

Comparative Analysis

CHK-339: Chinook therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

HYPEROXALURIA Key Companies

HYPEROXALURIA Key Products

HYPEROXALURIA- Unmet Needs

HYPEROXALURIA- Market Drivers and Barriers

HYPEROXALURIA- Future Perspectives and Conclusion

HYPEROXALURIA Analyst Views

HYPEROXALURIA Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for HYPEROXALURIA

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for HYPEROXALURIA
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Hyperoxaluria - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/HAAE443D85AEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HAAE443D85AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970